A5034709595- MicroRNA in disease regulation
- RNA modifications and cancer
- Cancer, Hypoxia, and Metabolism
- Cancer-related molecular mechanisms research
- Chemokine receptors and signaling
- Circular RNAs in diseases
- Cancer Mechanisms and Therapy
- Hepatocellular Carcinoma Treatment and Prognosis
- Gut microbiota and health
- Ferroptosis and cancer prognosis
- Liver Disease Diagnosis and Treatment
- Metabolism, Diabetes, and Cancer
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Pancreatic and Hepatic Oncology Research
- Caveolin-1 and cellular processes
- Autophagy in Disease and Therapy
- Diet and metabolism studies
University of Bologna
2023-2025
Policlinico S.Orsola-Malpighi
2023
Metabolic reprogramming is a well-known marker of cancer, and it represents an early event during hepatocellular carcinoma (HCC) development. The recent approval several molecular targeted agents has revolutionized the management advanced HCC patients. Nevertheless, lack circulating biomarkers still affects patient stratification to tailored treatments. In this context, there urgent need for aid treatment choice novel more effective therapeutic combinations avoid development drug-resistant...
The incidence of hepatocellular carcinoma (HCC) is increasing, and 40% patients are diagnosed at advanced stages. Over the past 5 years, number clinically available treatments has dramatically increased for HCC, making patient management particularly complex. Immune checkpoint inhibitors (ICIs) have improved overall survival patients, showing a durable treatment benefit over time different response pattern with respect to tyrosine kinase (TKIs). Although there in responder cases, sizeable...
Immunotherapy approval has revolutionized the management of hepatocellular carcinoma (HCC) patients. Sorafenib remains a first-line therapeutic option for those patients who are ineligible immunotherapy, but onset resistance compromises treatment efficacy, making need biomarkers more urgent. This study aims to investigate role miR-22 in metabolic reprogramming and as possible candidate HCC. QPCR analysis was performed HCC preclinical models. GLUT1 targeting by investigated cells functional...
The approval of immunotherapy has revolutionized the management hepatocellular carcinoma (HCC) patients. However, sorafenib remains a first-line therapeutic option for advanced patients and, in particular, not eligible immune checkpoint inhibitors, but its efficacy is limited by onset acquired resistance, highlighting urgent need predictive biomarkers. This study investigates role miR-22 metabolic reprogramming and potential as biomarker HCC. analysis expression was performed HCC preclinical...
The incidence of hepatocellular carcinoma (HCC) is increasing and 40% patients are diagnosed at advanced stages. Over the past 5 years, number clinical available treatments have dramatically increased for HCC, making patient management particularly complex. Immune checkpoint inhibitors (ICIs) improved overall survival showing a durable treatment benefit over time, different response pattern with respect to tyrosine kinase (TKIs). Although in responder cases, sizeable group primary...